Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation

Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation

Vemurafenib has been developed to target common BRAF mutation V600E. It also exerts activity towards some but not all rare BRAF substitutions. Proper cataloguing of drug-sensitive and -insensitive rare mutations remains a challenge, due to low occurrence of these events and inability of commercial P...

Full description

Bibliographic Details
Main Authors: Fedor V. Moiseyenko, Vitaliy V. Egorenkov, Mikhail M. Kramchaninov, Elizaveta V. Artemieva, Svetlana N. Aleksakhina, Maxim M. Holmatov, Vladimir M. Moiseyenko, Evgeny N. Imyanitov
Format: Article
Language:English
Published: Karger Publishers 2019-05-01
Series:Case Reports in Oncology
Subjects:
Melanoma
BRAF
Vemurafenib
K601E
Online Access:https://www.karger.com/Article/FullText/500481

Internet

https://www.karger.com/Article/FullText/500481

Similar Items